MKI67 and neoplasm: Second, the pharmacodynamics of KU60019 may be related as well to the different responses of the two types of orthotopic tumor used in17 and here: the GIC proliferation-stimulating effect exerted by KU60019 that reaches a peak 96 hours (four days) after drug infusion to the orthotopic tumor13, may in fact sustain the growth of the GIC-driven tumors well beyond that time, as indicated by the persistent, significant increase of KI67-positive cells 42 days after the last drug infusion (d108-d66; Fig. 5C,D).